Clinical trial · Observational
A Model for Predicting the Efficacy of Conversion Therapy for Patients With Colorectal Cancer Liver Metastases by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA
A Single-centre, Prospective, Cohort Trial of the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA for Establishing a Model for Predicting the Efficacy of Conversion Therapy for Patients With Unresectable Colorectal Cancer Liver Metastases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, the investigators establish a model for predicting the efficacy of conversion therapy for the patients with unresectable liver metastases of colorectal cancer based on the detection of 5-hydroxymethylcytosine (5-hmC) in training group and validate the effectiveness of the model using a validation group.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer With Liver Metastases | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The sensitivity and specificity of the model to predict the drug resistance
- timeFrame
- 4 months
- description
- Sensitivity and specificity of the model in predicting the drug resistance in conversion therapy for colorectal cancer with unresectable liver metastases
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven colorectal adenocarcinoma * Liver metastases were observed by abdominal pelvic CT and / or MRI with/without other distant metastases * The liver metastases assessed as unresectable lesions by multidisciplinary team * No other malignancies in medical history * Eastern cooperative oncology group score 0-2 * Informed consent Exclusion Criteria: * Patients received chemoradiotherapy or other anti-tumor therapy before being enrolled * Patients and/or family members can not understand or accept this study * Familial Adenomatous Polyposis, Lynch Syndrome, acute inflammatory bowel disease * Pregnancy or lactation * Unsuitable to take part in the clinical trial judged by doctors
References
Publications (0)
Data not yet available